Zimmer Biomet
(NYSE: ZBH)
announced today that it appointed David DeMartino as SVP, investor relations.
DeMartino reports to President and CEO Ivan Tornos within the leadership structure at the orthopedic giant. His appointment goes into effect on Sept. 9.
In this role, DeMartino holds responsibility for developing, refining and leading Zimmer Biomet’s investor relations strategy. He’s also tasked with cultivating relationships within the investment and financial community, according to a news release.
“We are excited to welcome David to Zimmer Biomet as our head of investor relations,” said Mr. Tornos. “His impressive career achievements and extensive knowledge of the medtech industry, as both an investor and in equity research, make him the ideal candidate for this strategically important position. As we navigate an exciting and pivotal time for our Company, David will play a critical role in leading our IR initiatives and enhancing our positive relationships across the investment community.”
DeMartino brings more than 25 years of experience in the healthcare industry, including asset management, equity research and investment banking. Before joining Zimmer Biomet, he served as chief strategy officer at Nyxoah, a medtech company aiming to treat obstructive sleep apnea.
Additionally, DeMartino had a stint as a portfolio manager at DNB Asset Management. He also held senior analyst positions at Velan Capital, Citadel and Pura Vida Investments. In those positions, he covered the medical device, biotechnology and healthcare technology industries. At Pura Vida, he also worked on private company investments.
Other experience includes sell-side equity research, initially covering healthcare facilities at Deusche Bank, then medical devices at Credit Suisse. DeMartino began his career with the Deutsche Bank Healthcare investment banking group.
